Summary
Pfizer Inc. announced on December 21, 2003, its agreement to acquire Esperion Therapeutics, Inc. This strategic move involves a cash tender offer for Esperion's shares at $35 per share, valuing the transaction at approximately $1.3 billion. Esperion Therapeutics is a biopharmaceutical company specializing in high-density lipoprotein (HDL) targeted therapies for cardiovascular disease. This acquisition signals Pfizer's commitment to expanding its presence in the cardiovascular therapeutic area, particularly by leveraging Esperion's development pipeline. Investors should monitor the progress of the tender offer and its impact on Pfizer's R&D capabilities and future product portfolio within the critical cardiovascular market.
Key Highlights
- 1Pfizer Inc. to acquire Esperion Therapeutics, Inc.
- 2Acquisition to be conducted via a cash tender offer.
- 3Offer price of $35 per share.
- 4Total transaction value of approximately $1.3 billion.
- 5Esperion Therapeutics focuses on HDL-targeted therapies for cardiovascular disease.
- 6The acquisition aims to bolster Pfizer's cardiovascular pipeline.
Frequently Asked Questions
The acquisition of Esperion Therapeutics is aimed at strengthening Pfizer's position in the cardiovascular disease market by acquiring Esperion's expertise and development pipeline in high-density lipoprotein (HDL) targeted therapies.
Pfizer intends to acquire Esperion Therapeutics through a cash tender offer valued at approximately $1.3 billion, with an offer price of $35 per share.
Esperion Therapeutics is a biopharmaceutical company focused on the development of therapies targeting high-density lipoprotein (HDL) for the treatment of cardiovascular diseases.
Pfizer announced its agreement to acquire Esperion Therapeutics on December 21, 2003. The Agreement between the two companies was dated December 19, 2003.